Merck May Sell Mature Drug Portfolio for $15B

Reuters sources are reporting that Merck is considering selling a large portfolio of off-patent drugs with a potential $15B pricetag.

Merck is working with an investment bank on the off-patent assets sale, which may attract interest from generic drugmakers, Reuters reports.

This news comes as Merck nears the potential sale of its $14B consumer healthcare business.

Merck's asset disposal efforts are in line with recent moves by drugmakers to sell off non-core divisions in order to better focus on core products.

 Read the Reuters press release

 

More News:

All news »

What are your comments?

Join the discussion today. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments